- Waldencast Announces Participation in CreatorIQ Connect Europe
- Waldencast Reports Fiscal Year 2023 Financial Results
- Waldencast Regains Compliance with Nasdaq Filing Requirements
- Waldencast Reports First Half 2023 Results
- Obagi Cosmeceuticals Announces the Launch of Daily Hydro-Drops® Rejuvenating Eye Gel Cream
- Waldencast Receives Positive Nasdaq Listing Determination
- Waldencast Announces New “Creative Council” of Industry Pioneers and Disruptors
- Dr. Suzan Obagi Appointed as Chief Medical Director at Obagi Cosmeceuticals, a Subsidiary of Waldencast plc.
- Waldencast Announces Participation in the TD Cowen Glowing Ahead: Beauty & Wellness Summit
- Waldencast Names Manuel Manfredi as Chief Financial Officer
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.91 |
---|---|
High | 5.13 |
Low | 4.90 |
Bid | 2.01 |
Offer | 6.90 |
Previous close | 4.87 |
Average volume | 84.43k |
---|---|
Shares outstanding | 122.08m |
Free float | 58.40m |
P/E (TTM) | -- |
Market cap | 594.51m USD |
EPS (TTM) | -3.40 USD |
Data delayed at least 15 minutes, as of May 01 2024 21:00 BST.
More ▼